Literature DB >> 23755967

Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects.

Shawna McCallin1, Shafiqul Alam Sarker, Caroline Barretto, Shamima Sultana, Bernard Berger, Sayeda Huq, Lutz Krause, Rodrigo Bibiloni, Bertrand Schmitt, Gloria Reuteler, Harald Brüssow.   

Abstract

Phage therapy has a long tradition in Eastern Europe, where preparations are comprised of complex phage cocktails whose compositions have not been described. We investigated the composition of a phage cocktail from the Russian pharmaceutical company Microgen targeting Escherichia coli/Proteus infections. Electron microscopy identified six phage types, with numerically T7-like phages dominating over T4-like phages. A metagenomic approach using taxonomical classification, reference mapping and de novo assembly identified 18 distinct phage types, including 7 genera of Podoviridae, 2 established and 2 proposed genera of Myoviridae, and 2 genera of Siphoviridae. De novo assembly yielded 7 contigs greater than 30 kb, including a 147-kb Myovirus genome and a 42-kb genome of a potentially new phage. Bioinformatic analysis did not reveal undesired genes and a small human volunteer trial did not associate adverse effects with oral phage exposure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteriophages; Escherichia coli; Fecal microbiota; Human phage therapy; Metagenomics; Safety

Mesh:

Year:  2013        PMID: 23755967     DOI: 10.1016/j.virol.2013.05.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  64 in total

1.  Amplification and purification of T4-like escherichia coli phages for phage therapy: from laboratory to pilot scale.

Authors:  Gilles Bourdin; Bertrand Schmitt; Laure Marvin Guy; Jacques-Edouard Germond; Sophie Zuber; Lise Michot; Gloria Reuteler; Harald Brüssow
Journal:  Appl Environ Microbiol       Date:  2013-12-20       Impact factor: 4.792

2.  Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections.

Authors:  Victor Krylov; Olga Shaburova; Elena Pleteneva; Sergey Krylov; Alla Kaplan; Maria Burkaltseva; Olga Polygach; Elena Chesnokova
Journal:  Virol Sin       Date:  2015-02-05       Impact factor: 4.327

Review 3.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

Review 4.  Problems with the concept of gut microbiota dysbiosis.

Authors:  Harald Brüssow
Journal:  Microb Biotechnol       Date:  2019-08-26       Impact factor: 5.813

5.  Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice.

Authors:  Nicolas Dufour; Raphaëlle Delattre; Anne Chevallereau; Jean-Damien Ricard; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 6.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

Review 7.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 8.  Intestinal virome and therapeutic potential of bacteriophages in liver disease.

Authors:  Cynthia L Hsu; Yi Duan; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-08-24       Impact factor: 25.083

Review 9.  Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective.

Authors:  Gursneh Kaur; Ritika Agarwal; Rakesh Kumar Sharma
Journal:  Food Environ Virol       Date:  2021-06-12       Impact factor: 2.778

Review 10.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.